Summary of Masimo's Conference Call Company Overview - **Company**: Masimo - **Industry**: Medical Devices Key Points and Arguments Leadership and Strategic Focus - Masimo is undergoing a leadership transition with a new CEO, aiming to realign and optimize its cost structure while focusing on core growth areas within hospital settings [2][4] - The company plans to concentrate on its flagship product, pulse oximetry, which accounts for over 70% of revenues, alongside growth in rainbow hemodynamics, brain monitoring, capnography, gas monitoring, and automation [2][3] Financial Performance and Growth Expectations - Masimo expects a long-term revenue growth of 7% to 10% with aspirations to achieve 30% operating margins [4] - In Q1, capital growth was reported at 32%, significantly higher than the expected flat to mid-single-digit growth, attributed to a large tender order from a long-term customer [8][9] - Consumable growth is anticipated to be in the high single-digit to low double-digit range, with Q1 showing strong underlying growth despite some lumpiness in orders [10] Operational Challenges and Cyber Incident - The company is recovering from a cyber incident, with critical systems being prioritized for restoration. There is no expected impact on annual guidance, although some near-term disruptions are anticipated [15][17] - The company is quantifying the cost impact of the cyber incident, with insurance expected to cover a significant portion of the expenses [19] Tariffs and Cost Management - Masimo sources about 5% of its cost of goods from China, with a potential reduction in tariff exposure due to recent changes in tariff rates [26][27] - The company is focusing on cost mitigation strategies, including pricing adjustments and optimizing supply chains, particularly in Mexico and Malaysia [32][35] Margin Expansion and Future Outlook - Operating margins in Q1 were reported at 28.8%, with a goal to maintain margins between 28% and 28.5% for the year [41] - The long-term goal is to achieve gross margins closer to 66%, with aspirations for 70% despite setbacks from COVID-19 and inflationary pressures [40][43] Litigation Updates - Ongoing litigation with Apple includes patent infringement cases, with significant developments expected in the coming months [52][54] Capital Deployment Strategy - The company plans to prioritize share buybacks and improve liquidity while evaluating opportunities for tuck-in technologies to enhance its core business [48][49] Conclusion - Masimo is optimistic about its position for the year, emphasizing strong fundamentals and a commitment to margin expansion and reinvestment for growth [56][57]

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Gr ...

Masimo Corporation (MASI) delivered adjusted earnings per share (EPS) of $1.36 in the first quarter of 2025, up 56.3% year over year. The figure beat the Zacks Consensus Estimate by 9.7%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The adjustments include acquired intangible asset amortization, and acquisitions, integrations, divestitures, and related costs, among others.GAAP EPS for the quarter was 86 cents, up 45.8% from the year-ago period’s EPS of 59 cents.MASI’s Revenues in ...

Masimo (MASI) came out with quarterly earnings of $1.36 per share, beating the Zacks Consensus Estimate of $1.24 per share. This compares to earnings of $0.77 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.68%. A quarter ago, it was expected that this medical technology company would post earnings of $1.49 per share when it actually produced earnings of $1.80, delivering a surprise of 20.81%.Over the last four quarters, the ...

Masimo (MASI) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Eli Kammerman - Vice President of Business Development & Investor RelationsKatie Szyman - CEOMicah Young - Executive VP & CFORick Wise - Managing Director - Medical Technology & SuppliesMatt Taylor - Managing Director Conference Call Participants Vik Chopra - AnalystJason Bednar - Senior Research AnalystMike Matson - Senior Equity Research AnalystMike Polark - Senior Equity Research Analyst - Medical Devices Operator Good afte ...

First Quarter 2025 Earnings May 6, 2025 3 1 Safe Harbor Statement Forward-Looking Statements: This presentation contains forward-looking statements within the meaning of federal securities laws, including, among others, statements about our expectations, plans, strategies or prospects. We generally use the words "may," "will," "expect," "believe," "anticipate," "plan," "estimate," "project," "assume," "guide," "target," "forecast," "see," "seek," "can," "should," "could," "would," "intend," "predict," "pote ...

Masimo (MASI) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Speaker0 Good afternoon, ladies and gentlemen, and welcome to Masimo's First Quarter twenty twenty five Earnings Conference Call. The company's press release is available at www.masimo.com. At this time, all lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I'm pleased to introduce Eli Hammerman, Masimo's Vice President of Business Development and Investor Rela ...

Exhibit 99.1 Irvine, California, May 6, 2025 - Masimo Corporation (Nasdaq: MASI) today announced its financial results for the first quarter ended March 29, 2025. First Quarter 2025 Results From Continuing Operations : (1) First Quarter 2025 Results From Discontinued Operations : (2) Masimo Reports First Quarter 2025 Results ■ GAAP loss from discontinued operations, net of tax was ($218) million, which included an impairment of intangibles of $295 million for the non-healthcare consumer business. Katie Szym ...

Core Insights - Masimo (MASI) has consistently surpassed earnings estimates, averaging a beat of 18.74% over the last two quarters [1][5] - In the most recent quarter, Masimo reported earnings of $1.80 per share, exceeding the expected $1.49 per share by 20.81% [2] - The previous quarter also saw Masimo outperforming estimates, reporting $0.98 per share against an expectation of $0.84 per share, a surprise of 16.67% [2] Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Masimo, with a positive Zacks Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5][8] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise [6] - Masimo currently holds an Earnings ESP of +0.64%, suggesting analysts are optimistic about the company's earnings prospects [8] Zacks Rank and Earnings ESP - The combination of a positive Earnings ESP and a Zacks Rank 1 (Strong Buy) indicates a high probability of another earnings beat for Masimo [8] - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [7] - A negative Earnings ESP does not necessarily indicate an earnings miss, but it reduces the predictive power of the metric [8]

One stock that might be an intriguing choice for investors right now is Masimo Corporation (MASI) . This is because this security in the Medical - Instruments space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the M ...